Thursday, May 31, 2018 at 12:00 PM
This grand round has already taken place.
May 31st, 2018 1.00 AMA PRA Category 1 Credit Hours
Description
Mutations in the p53 tumor suppressor gene are the most prevalent genetic events in human Her2-positive Breast Cancer and are associated with poor prognosis and survival. In early stages of Cancer, a p53 mutation in one allele is often followed by loss of heterozygosity (LOH) in the second allele. Despite a strong notion that p53 mutations with subsequent LOH are driving events in Breast Cancer, the molecular mechanism of p53 LOH, its translational significance, and role in Breast Cancer development and progression are yet to be comprehensively evaluated, especially in the context of conventional genotoxic modalities.
Dates and Times
Start: 5/31/2018 12:00 PM
End: 5/31/2018 1:00 PM
Objectives
1) To determine the effect of DNA-damaging radiation therapy on p53 LOH and tumorigenesis in ErbB2-driven mammary tumors with regard to p53 status.
2) To define the mechanism by which mutp53 in promotes p53 LOH in ErbB2 mammary tumors.
3) To identify the impact of mutp53-mTOR signaling axis on genomic instability in retrospective clinical study of HER2 human Breast Cancer
Speakers
Location
Pathology Classroom
Basic Science Tower
Level 9 Room 145
Stony Brook, NY 11950
Accreditation
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Need help with this Grand Round Session?
Please contact the Grand Round coordinator listed below:
Leslie Moehringer
Department: Pathology
Phone: (631) 444-5931
Email: Leslie.Moehringer@stonybrookmedicine.edu